It's safe to say that Marvel is back, raves Varun Khanvilkar.
Kareena Kapoor attends a Bvlgari event in style.
Indian drugmaker Dr Reddy's Laboratories Ltd said on Wednesday it has filed with the US Food and Drug Administration to market a generic version of Aventis Pharmaceuticals' anti-allergy drug Allegra.
Indian pharmaceutical companies are stepping up their efforts to combat the problem of counterfeit drugs, employing a variety of strategies, from packaging innovations to engaging private investigation agencies. The stakes are high, as counterfeit medicines not only harm consumers but also tarnish the reputation of leading brands.
The top 300 pharmaceutical brands in the country will now bear a quick response (QR) code on their packaging to rein in spurious drugs and ensure better traceability.
The patent relates to the manufacturing process for the active ingredient in Sanofi-Aventis' Allegra and Allegra-D drug products. Both Dr Reddys and Sandoz are known to be marketing these products in the US.
Announcing the news on social media, Symonds, 32, said the baby was named after the UK Prime Minister's grandfather Wilfred and her grandfather Lawrie, with Nicholas a nod to the National Health Service doctors - Dr Nick Price and Dr Nick Hart.
Dr Reddy's Laboratories received a major setback in the US, as a court there granted a motion seeking a preliminary injunction to block the launch of its generic version of Sanofi-Aventis' anti-allergic drug, Allegra D24.
A look at some interesting moments from the 10-day fashion gala in New York.
An ardent backer of Brexit, Boris Johnson has a reputation for brashness, bombast, bending the truth, and really bad hair, which has earned him more than a few comparisons to United States President Donald Trump (who also happens to be a fan of his). Here are some interesting facts about BoJo, as he is called by the British media.
As Michael Kors takes over the Italian fashion house, we take a trip down memory lane and look back at the Versace story.
It is advisable to stick to mid-caps with sustainable financial metrics rather than those offering the promise of faster growth.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances